Trial reportCirculation2017
Randomized Comparison of Ridaforolimus- and Zotarolimus-Eluting Coronary Stents in Patients With Coronary Artery Disease: Primary Results From the BIONICS Trial (BioNIR Ridaforolimus-Eluting Coronary Stent System in Coronary Stenosis).
Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled Trial
In one paragraph
Trial report in Circulation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01995487 (BioNIR Ridaforolimus Eluting Coronary Stent System), which is not on this map. Cited by 19 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
6.0field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
BioNIR Ridaforolimus Eluting Coronary Stent System (BioNIR) In Coronary Stenosis Trial
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Critical evaluation of stents in coronary angioplasty: a systematic review.Biomedical engineering online · 2021Pooled it
- Site-Specific Antithrombotic Therapy: 24-Month Outcomes of the Randomized DESyne BDS Plus Trial Using a Novel Triple-Drug Eluting Coronary Implant With Two Anticoagulants and Sirolimus.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2025Trial
- Everolimus-eluting versus biolimus-eluting stents with biodegradable polymers in unselected patients undergoing percutaneous coronary intervention: five-year results of the randomised, non-inferiority SORT OUT VIII trial.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2025Trial
- Percutaneous Coronary Interventions Using a Ridaforolimus-Eluting Stent in Patients at High Bleeding Risk.Journal of the American Heart Association · 2024Trial
- Cardiovascular stent technologies for coronary and valvular heart disease: the potential of 3D printing for stent fabrication.Nature reviews. Cardiology · 2026Review
- Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents in US Patients Undergoing Coronary Revascularization: 2-Year Outcomes From the BIOFLOW VII Trial.Journal of the Society for Cardiovascular Angiography & Interventions · 2026Article
- Type 2 Myocardial Infarction: Navigating Diagnostic Pathways and Therapeutic Crossroads Between Invasive and Conservative Strategies.Journal of clinical medicine · 2026Review
- Comparison of Ridaforolimus-Eluting and Zotarolimus-Eluting Coronary Stents: 5-Year Outcomes From the BIONICS and NIREUS Trials.Journal of the American Heart Association · 2024Article
- Endovascular Drug Delivery.Life (Basel, Switzerland) · 2024Review
- Utility of the ACC/AHA Lesion Classification to Predict Outcomes After Contemporary DES Treatment: Individual Patient Data Pooled Analysis From 7 Randomized Trials.Journal of the American Heart Association · 2022Article
- Delivery of rivaroxaban and chitosan rapamycin microparticle with dual antithrombosis and antiproliferation functions inhibits venous neointimal hyperplasia.Drug delivery · 2022Article
- Shortened dual antiplatelet therapy in contemporary percutaneous coronary intervention era.World journal of cardiology · 2021Review
- Comparison of acute thrombogenicity and albumin adsorption in three different durable polymer coronary drug-eluting stents.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2021Article
- Vascular Lesion-Specific Drug Delivery Systems: JACC State-of-the-Art Review.Journal of the American College of Cardiology · 2021Review
- Ultrathin (60 μm), ultralong (≥40 mm) sirolimus-eluting stent: study of clinical and safety profiles among real-world patients.Anatolian journal of cardiology · 2021Article
- Drug-eluting coronary stents: insights from preclinical and pathology studies.Nature reviews. Cardiology · 2020Review
- Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk.European heart journal · 2019Article
- Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention.Circulation · 2019Review
- Incidence and predictors of target lesion failure in patients undergoing contemporary DES implantation-Individual patient data pooled analysis from 6 randomized controlled trials.American heart journal · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 1 institution in 1 country.
David E KandzariFrom Piedmont Heart Institute, Atlanta, GA (D.E.K.); Maasstad Hospital, Rotterdam, The Netherlands (P.C.S.); Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia (M.P.L.); Columbia University Medical Center and the Cardiovascular Research Foundation, New York (O.B.-Y., M.P., M.O.O., P.G., M.B.L., G.W.S.); Tel Aviv Medical Center, Israel (S.B.); Victoria Heart Institute Foundation, British Columbia, Canada (S.D.R.); Kaplan Medical Center, Rehovot, Israel (M.J.); Rabin Medical Center, Petach Tikva, Israel (R.K.); Centre Hospitalier Universitaire de Quebec, Canada (R.B.); Hospital Meixoeiro, Vigo, Spain (A.I.); Hadassah Hebrew University Medical Center, Jerusalem, Israel (H.D., G.Y.P.); MediQuest Research Group, Ocala, FL (R.F.); North Shore University Hospital, New York (R.J.); Victoria Heart and Vascular Center, TX (H.C.); Medinol Ltd, Tel Aviv, Israel (G.Y.P.); Massachusetts Institute of Technology, Cambridge (M.B., E.R.E.); and CBSET Inc, Lexington, MA (P.M.). david.kandzari@piedmont.org.
Pieter C SmitsFrom Piedmont Heart Institute, Atlanta, GA (D.E.K.); Maasstad Hospital, Rotterdam, The Netherlands (P.C.S.); Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia (M.P.L.); Columbia University Medical Center and the Cardiovascular Research Foundation, New York (O.B.-Y., M.P., M.O.O., P.G., M.B.L., G.W.S.); Tel Aviv Medical Center, Israel (S.B.); Victoria Heart Institute Foundation, British Columbia, Canada (S.D.R.); Kaplan Medical Center, Rehovot, Israel (M.J.); Rabin Medical Center, Petach Tikva, Israel (R.K.); Centre Hospitalier Universitaire de Quebec, Canada (R.B.); Hospital Meixoeiro, Vigo, Spain (A.I.); Hadassah Hebrew University Medical Center, Jerusalem, Israel (H.D., G.Y.P.); MediQuest Research Group, Ocala, FL (R.F.); North Shore University Hospital, New York (R.J.); Victoria Heart and Vascular Center, TX (H.C.); Medinol Ltd, Tel Aviv, Israel (G.Y.P.); Massachusetts Institute of Technology, Cambridge (M.B., E.R.E.); and CBSET Inc, Lexington, MA (P.M.).
Michael P LoveFrom Piedmont Heart Institute, Atlanta, GA (D.E.K.); Maasstad Hospital, Rotterdam, The Netherlands (P.C.S.); Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia (M.P.L.); Columbia University Medical Center and the Cardiovascular Research Foundation, New York (O.B.-Y., M.P., M.O.O., P.G., M.B.L., G.W.S.); Tel Aviv Medical Center, Israel (S.B.); Victoria Heart Institute Foundation, British Columbia, Canada (S.D.R.); Kaplan Medical Center, Rehovot, Israel (M.J.); Rabin Medical Center, Petach Tikva, Israel (R.K.); Centre Hospitalier Universitaire de Quebec, Canada (R.B.); Hospital Meixoeiro, Vigo, Spain (A.I.); Hadassah Hebrew University Medical Center, Jerusalem, Israel (H.D., G.Y.P.); MediQuest Research Group, Ocala, FL (R.F.); North Shore University Hospital, New York (R.J.); Victoria Heart and Vascular Center, TX (H.C.); Medinol Ltd, Tel Aviv, Israel (G.Y.P.); Massachusetts Institute of Technology, Cambridge (M.B., E.R.E.); and CBSET Inc, Lexington, MA (P.M.).
Ori Ben-YehudaFrom Piedmont Heart Institute, Atlanta, GA (D.E.K.); Maasstad Hospital, Rotterdam, The Netherlands (P.C.S.); Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia (M.P.L.); Columbia University Medical Center and the Cardiovascular Research Foundation, New York (O.B.-Y., M.P., M.O.O., P.G., M.B.L., G.W.S.); Tel Aviv Medical Center, Israel (S.B.); Victoria Heart Institute Foundation, British Columbia, Canada (S.D.R.); Kaplan Medical Center, Rehovot, Israel (M.J.); Rabin Medical Center, Petach Tikva, Israel (R.K.); Centre Hospitalier Universitaire de Quebec, Canada (R.B.); Hospital Meixoeiro, Vigo, Spain (A.I.); Hadassah Hebrew University Medical Center, Jerusalem, Israel (H.D., G.Y.P.); MediQuest Research Group, Ocala, FL (R.F.); North Shore University Hospital, New York (R.J.); Victoria Heart and Vascular Center, TX (H.C.); Medinol Ltd, Tel Aviv, Israel (G.Y.P.); Massachusetts Institute of Technology, Cambridge (M.B., E.R.E.); and CBSET Inc, Lexington, MA (P.M.).
Shmuel BanaiFrom Piedmont Heart Institute, Atlanta, GA (D.E.K.); Maasstad Hospital, Rotterdam, The Netherlands (P.C.S.); Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia (M.P.L.); Columbia University Medical Center and the Cardiovascular Research Foundation, New York (O.B.-Y., M.P., M.O.O., P.G., M.B.L., G.W.S.); Tel Aviv Medical Center, Israel (S.B.); Victoria Heart Institute Foundation, British Columbia, Canada (S.D.R.); Kaplan Medical Center, Rehovot, Israel (M.J.); Rabin Medical Center, Petach Tikva, Israel (R.K.); Centre Hospitalier Universitaire de Quebec, Canada (R.B.); Hospital Meixoeiro, Vigo, Spain (A.I.); Hadassah Hebrew University Medical Center, Jerusalem, Israel (H.D., G.Y.P.); MediQuest Research Group, Ocala, FL (R.F.); North Shore University Hospital, New York (R.J.); Victoria Heart and Vascular Center, TX (H.C.); Medinol Ltd, Tel Aviv, Israel (G.Y.P.); Massachusetts Institute of Technology, Cambridge (M.B., E.R.E.); and CBSET Inc, Lexington, MA (P.M.).
Simon D RobinsonFrom Piedmont Heart Institute, Atlanta, GA (D.E.K.); Maasstad Hospital, Rotterdam, The Netherlands (P.C.S.); Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia (M.P.L.); Columbia University Medical Center and the Cardiovascular Research Foundation, New York (O.B.-Y., M.P., M.O.O., P.G., M.B.L., G.W.S.); Tel Aviv Medical Center, Israel (S.B.); Victoria Heart Institute Foundation, British Columbia, Canada (S.D.R.); Kaplan Medical Center, Rehovot, Israel (M.J.); Rabin Medical Center, Petach Tikva, Israel (R.K.); Centre Hospitalier Universitaire de Quebec, Canada (R.B.); Hospital Meixoeiro, Vigo, Spain (A.I.); Hadassah Hebrew University Medical Center, Jerusalem, Israel (H.D., G.Y.P.); MediQuest Research Group, Ocala, FL (R.F.); North Shore University Hospital, New York (R.J.); Victoria Heart and Vascular Center, TX (H.C.); Medinol Ltd, Tel Aviv, Israel (G.Y.P.); Massachusetts Institute of Technology, Cambridge (M.B., E.R.E.); and CBSET Inc, Lexington, MA (P.M.).
Michael JonasFrom Piedmont Heart Institute, Atlanta, GA (D.E.K.); Maasstad Hospital, Rotterdam, The Netherlands (P.C.S.); Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia (M.P.L.); Columbia University Medical Center and the Cardiovascular Research Foundation, New York (O.B.-Y., M.P., M.O.O., P.G., M.B.L., G.W.S.); Tel Aviv Medical Center, Israel (S.B.); Victoria Heart Institute Foundation, British Columbia, Canada (S.D.R.); Kaplan Medical Center, Rehovot, Israel (M.J.); Rabin Medical Center, Petach Tikva, Israel (R.K.); Centre Hospitalier Universitaire de Quebec, Canada (R.B.); Hospital Meixoeiro, Vigo, Spain (A.I.); Hadassah Hebrew University Medical Center, Jerusalem, Israel (H.D., G.Y.P.); MediQuest Research Group, Ocala, FL (R.F.); North Shore University Hospital, New York (R.J.); Victoria Heart and Vascular Center, TX (H.C.); Medinol Ltd, Tel Aviv, Israel (G.Y.P.); Massachusetts Institute of Technology, Cambridge (M.B., E.R.E.); and CBSET Inc, Lexington, MA (P.M.).
Ran KornowskiFrom Piedmont Heart Institute, Atlanta, GA (D.E.K.); Maasstad Hospital, Rotterdam, The Netherlands (P.C.S.); Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia (M.P.L.); Columbia University Medical Center and the Cardiovascular Research Foundation, New York (O.B.-Y., M.P., M.O.O., P.G., M.B.L., G.W.S.); Tel Aviv Medical Center, Israel (S.B.); Victoria Heart Institute Foundation, British Columbia, Canada (S.D.R.); Kaplan Medical Center, Rehovot, Israel (M.J.); Rabin Medical Center, Petach Tikva, Israel (R.K.); Centre Hospitalier Universitaire de Quebec, Canada (R.B.); Hospital Meixoeiro, Vigo, Spain (A.I.); Hadassah Hebrew University Medical Center, Jerusalem, Israel (H.D., G.Y.P.); MediQuest Research Group, Ocala, FL (R.F.); North Shore University Hospital, New York (R.J.); Victoria Heart and Vascular Center, TX (H.C.); Medinol Ltd, Tel Aviv, Israel (G.Y.P.); Massachusetts Institute of Technology, Cambridge (M.B., E.R.E.); and CBSET Inc, Lexington, MA (P.M.).
Rodrigo BagurFrom Piedmont Heart Institute, Atlanta, GA (D.E.K.); Maasstad Hospital, Rotterdam, The Netherlands (P.C.S.); Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia (M.P.L.); Columbia University Medical Center and the Cardiovascular Research Foundation, New York (O.B.-Y., M.P., M.O.O., P.G., M.B.L., G.W.S.); Tel Aviv Medical Center, Israel (S.B.); Victoria Heart Institute Foundation, British Columbia, Canada (S.D.R.); Kaplan Medical Center, Rehovot, Israel (M.J.); Rabin Medical Center, Petach Tikva, Israel (R.K.); Centre Hospitalier Universitaire de Quebec, Canada (R.B.); Hospital Meixoeiro, Vigo, Spain (A.I.); Hadassah Hebrew University Medical Center, Jerusalem, Israel (H.D., G.Y.P.); MediQuest Research Group, Ocala, FL (R.F.); North Shore University Hospital, New York (R.J.); Victoria Heart and Vascular Center, TX (H.C.); Medinol Ltd, Tel Aviv, Israel (G.Y.P.); Massachusetts Institute of Technology, Cambridge (M.B., E.R.E.); and CBSET Inc, Lexington, MA (P.M.).
Andres IniguezFrom Piedmont Heart Institute, Atlanta, GA (D.E.K.); Maasstad Hospital, Rotterdam, The Netherlands (P.C.S.); Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia (M.P.L.); Columbia University Medical Center and the Cardiovascular Research Foundation, New York (O.B.-Y., M.P., M.O.O., P.G., M.B.L., G.W.S.); Tel Aviv Medical Center, Israel (S.B.); Victoria Heart Institute Foundation, British Columbia, Canada (S.D.R.); Kaplan Medical Center, Rehovot, Israel (M.J.); Rabin Medical Center, Petach Tikva, Israel (R.K.); Centre Hospitalier Universitaire de Quebec, Canada (R.B.); Hospital Meixoeiro, Vigo, Spain (A.I.); Hadassah Hebrew University Medical Center, Jerusalem, Israel (H.D., G.Y.P.); MediQuest Research Group, Ocala, FL (R.F.); North Shore University Hospital, New York (R.J.); Victoria Heart and Vascular Center, TX (H.C.); Medinol Ltd, Tel Aviv, Israel (G.Y.P.); Massachusetts Institute of Technology, Cambridge (M.B., E.R.E.); and CBSET Inc, Lexington, MA (P.M.).
Haim DanenbergFrom Piedmont Heart Institute, Atlanta, GA (D.E.K.); Maasstad Hospital, Rotterdam, The Netherlands (P.C.S.); Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia (M.P.L.); Columbia University Medical Center and the Cardiovascular Research Foundation, New York (O.B.-Y., M.P., M.O.O., P.G., M.B.L., G.W.S.); Tel Aviv Medical Center, Israel (S.B.); Victoria Heart Institute Foundation, British Columbia, Canada (S.D.R.); Kaplan Medical Center, Rehovot, Israel (M.J.); Rabin Medical Center, Petach Tikva, Israel (R.K.); Centre Hospitalier Universitaire de Quebec, Canada (R.B.); Hospital Meixoeiro, Vigo, Spain (A.I.); Hadassah Hebrew University Medical Center, Jerusalem, Israel (H.D., G.Y.P.); MediQuest Research Group, Ocala, FL (R.F.); North Shore University Hospital, New York (R.J.); Victoria Heart and Vascular Center, TX (H.C.); Medinol Ltd, Tel Aviv, Israel (G.Y.P.); Massachusetts Institute of Technology, Cambridge (M.B., E.R.E.); and CBSET Inc, Lexington, MA (P.M.).
Robert FeldmanFrom Piedmont Heart Institute, Atlanta, GA (D.E.K.); Maasstad Hospital, Rotterdam, The Netherlands (P.C.S.); Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia (M.P.L.); Columbia University Medical Center and the Cardiovascular Research Foundation, New York (O.B.-Y., M.P., M.O.O., P.G., M.B.L., G.W.S.); Tel Aviv Medical Center, Israel (S.B.); Victoria Heart Institute Foundation, British Columbia, Canada (S.D.R.); Kaplan Medical Center, Rehovot, Israel (M.J.); Rabin Medical Center, Petach Tikva, Israel (R.K.); Centre Hospitalier Universitaire de Quebec, Canada (R.B.); Hospital Meixoeiro, Vigo, Spain (A.I.); Hadassah Hebrew University Medical Center, Jerusalem, Israel (H.D., G.Y.P.); MediQuest Research Group, Ocala, FL (R.F.); North Shore University Hospital, New York (R.J.); Victoria Heart and Vascular Center, TX (H.C.); Medinol Ltd, Tel Aviv, Israel (G.Y.P.); Massachusetts Institute of Technology, Cambridge (M.B., E.R.E.); and CBSET Inc, Lexington, MA (P.M.).
Rajiv JauharFrom Piedmont Heart Institute, Atlanta, GA (D.E.K.); Maasstad Hospital, Rotterdam, The Netherlands (P.C.S.); Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia (M.P.L.); Columbia University Medical Center and the Cardiovascular Research Foundation, New York (O.B.-Y., M.P., M.O.O., P.G., M.B.L., G.W.S.); Tel Aviv Medical Center, Israel (S.B.); Victoria Heart Institute Foundation, British Columbia, Canada (S.D.R.); Kaplan Medical Center, Rehovot, Israel (M.J.); Rabin Medical Center, Petach Tikva, Israel (R.K.); Centre Hospitalier Universitaire de Quebec, Canada (R.B.); Hospital Meixoeiro, Vigo, Spain (A.I.); Hadassah Hebrew University Medical Center, Jerusalem, Israel (H.D., G.Y.P.); MediQuest Research Group, Ocala, FL (R.F.); North Shore University Hospital, New York (R.J.); Victoria Heart and Vascular Center, TX (H.C.); Medinol Ltd, Tel Aviv, Israel (G.Y.P.); Massachusetts Institute of Technology, Cambridge (M.B., E.R.E.); and CBSET Inc, Lexington, MA (P.M.).
Harish ChandnaFrom Piedmont Heart Institute, Atlanta, GA (D.E.K.); Maasstad Hospital, Rotterdam, The Netherlands (P.C.S.); Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia (M.P.L.); Columbia University Medical Center and the Cardiovascular Research Foundation, New York (O.B.-Y., M.P., M.O.O., P.G., M.B.L., G.W.S.); Tel Aviv Medical Center, Israel (S.B.); Victoria Heart Institute Foundation, British Columbia, Canada (S.D.R.); Kaplan Medical Center, Rehovot, Israel (M.J.); Rabin Medical Center, Petach Tikva, Israel (R.K.); Centre Hospitalier Universitaire de Quebec, Canada (R.B.); Hospital Meixoeiro, Vigo, Spain (A.I.); Hadassah Hebrew University Medical Center, Jerusalem, Israel (H.D., G.Y.P.); MediQuest Research Group, Ocala, FL (R.F.); North Shore University Hospital, New York (R.J.); Victoria Heart and Vascular Center, TX (H.C.); Medinol Ltd, Tel Aviv, Israel (G.Y.P.); Massachusetts Institute of Technology, Cambridge (M.B., E.R.E.); and CBSET Inc, Lexington, MA (P.M.).
Manish ParikhFrom Piedmont Heart Institute, Atlanta, GA (D.E.K.); Maasstad Hospital, Rotterdam, The Netherlands (P.C.S.); Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia (M.P.L.); Columbia University Medical Center and the Cardiovascular Research Foundation, New York (O.B.-Y., M.P., M.O.O., P.G., M.B.L., G.W.S.); Tel Aviv Medical Center, Israel (S.B.); Victoria Heart Institute Foundation, British Columbia, Canada (S.D.R.); Kaplan Medical Center, Rehovot, Israel (M.J.); Rabin Medical Center, Petach Tikva, Israel (R.K.); Centre Hospitalier Universitaire de Quebec, Canada (R.B.); Hospital Meixoeiro, Vigo, Spain (A.I.); Hadassah Hebrew University Medical Center, Jerusalem, Israel (H.D., G.Y.P.); MediQuest Research Group, Ocala, FL (R.F.); North Shore University Hospital, New York (R.J.); Victoria Heart and Vascular Center, TX (H.C.); Medinol Ltd, Tel Aviv, Israel (G.Y.P.); Massachusetts Institute of Technology, Cambridge (M.B., E.R.E.); and CBSET Inc, Lexington, MA (P.M.).
Gidon Y PerlmanFrom Piedmont Heart Institute, Atlanta, GA (D.E.K.); Maasstad Hospital, Rotterdam, The Netherlands (P.C.S.); Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia (M.P.L.); Columbia University Medical Center and the Cardiovascular Research Foundation, New York (O.B.-Y., M.P., M.O.O., P.G., M.B.L., G.W.S.); Tel Aviv Medical Center, Israel (S.B.); Victoria Heart Institute Foundation, British Columbia, Canada (S.D.R.); Kaplan Medical Center, Rehovot, Israel (M.J.); Rabin Medical Center, Petach Tikva, Israel (R.K.); Centre Hospitalier Universitaire de Quebec, Canada (R.B.); Hospital Meixoeiro, Vigo, Spain (A.I.); Hadassah Hebrew University Medical Center, Jerusalem, Israel (H.D., G.Y.P.); MediQuest Research Group, Ocala, FL (R.F.); North Shore University Hospital, New York (R.J.); Victoria Heart and Vascular Center, TX (H.C.); Medinol Ltd, Tel Aviv, Israel (G.Y.P.); Massachusetts Institute of Technology, Cambridge (M.B., E.R.E.); and CBSET Inc, Lexington, MA (P.M.).
Mercedes BalcellsFrom Piedmont Heart Institute, Atlanta, GA (D.E.K.); Maasstad Hospital, Rotterdam, The Netherlands (P.C.S.); Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia (M.P.L.); Columbia University Medical Center and the Cardiovascular Research Foundation, New York (O.B.-Y., M.P., M.O.O., P.G., M.B.L., G.W.S.); Tel Aviv Medical Center, Israel (S.B.); Victoria Heart Institute Foundation, British Columbia, Canada (S.D.R.); Kaplan Medical Center, Rehovot, Israel (M.J.); Rabin Medical Center, Petach Tikva, Israel (R.K.); Centre Hospitalier Universitaire de Quebec, Canada (R.B.); Hospital Meixoeiro, Vigo, Spain (A.I.); Hadassah Hebrew University Medical Center, Jerusalem, Israel (H.D., G.Y.P.); MediQuest Research Group, Ocala, FL (R.F.); North Shore University Hospital, New York (R.J.); Victoria Heart and Vascular Center, TX (H.C.); Medinol Ltd, Tel Aviv, Israel (G.Y.P.); Massachusetts Institute of Technology, Cambridge (M.B., E.R.E.); and CBSET Inc, Lexington, MA (P.M.).
Peter MarkhamFrom Piedmont Heart Institute, Atlanta, GA (D.E.K.); Maasstad Hospital, Rotterdam, The Netherlands (P.C.S.); Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia (M.P.L.); Columbia University Medical Center and the Cardiovascular Research Foundation, New York (O.B.-Y., M.P., M.O.O., P.G., M.B.L., G.W.S.); Tel Aviv Medical Center, Israel (S.B.); Victoria Heart Institute Foundation, British Columbia, Canada (S.D.R.); Kaplan Medical Center, Rehovot, Israel (M.J.); Rabin Medical Center, Petach Tikva, Israel (R.K.); Centre Hospitalier Universitaire de Quebec, Canada (R.B.); Hospital Meixoeiro, Vigo, Spain (A.I.); Hadassah Hebrew University Medical Center, Jerusalem, Israel (H.D., G.Y.P.); MediQuest Research Group, Ocala, FL (R.F.); North Shore University Hospital, New York (R.J.); Victoria Heart and Vascular Center, TX (H.C.); Medinol Ltd, Tel Aviv, Israel (G.Y.P.); Massachusetts Institute of Technology, Cambridge (M.B., E.R.E.); and CBSET Inc, Lexington, MA (P.M.).
Melek Ozgu OzanFrom Piedmont Heart Institute, Atlanta, GA (D.E.K.); Maasstad Hospital, Rotterdam, The Netherlands (P.C.S.); Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia (M.P.L.); Columbia University Medical Center and the Cardiovascular Research Foundation, New York (O.B.-Y., M.P., M.O.O., P.G., M.B.L., G.W.S.); Tel Aviv Medical Center, Israel (S.B.); Victoria Heart Institute Foundation, British Columbia, Canada (S.D.R.); Kaplan Medical Center, Rehovot, Israel (M.J.); Rabin Medical Center, Petach Tikva, Israel (R.K.); Centre Hospitalier Universitaire de Quebec, Canada (R.B.); Hospital Meixoeiro, Vigo, Spain (A.I.); Hadassah Hebrew University Medical Center, Jerusalem, Israel (H.D., G.Y.P.); MediQuest Research Group, Ocala, FL (R.F.); North Shore University Hospital, New York (R.J.); Victoria Heart and Vascular Center, TX (H.C.); Medinol Ltd, Tel Aviv, Israel (G.Y.P.); Massachusetts Institute of Technology, Cambridge (M.B., E.R.E.); and CBSET Inc, Lexington, MA (P.M.).
Philippe GenereuxFrom Piedmont Heart Institute, Atlanta, GA (D.E.K.); Maasstad Hospital, Rotterdam, The Netherlands (P.C.S.); Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia (M.P.L.); Columbia University Medical Center and the Cardiovascular Research Foundation, New York (O.B.-Y., M.P., M.O.O., P.G., M.B.L., G.W.S.); Tel Aviv Medical Center, Israel (S.B.); Victoria Heart Institute Foundation, British Columbia, Canada (S.D.R.); Kaplan Medical Center, Rehovot, Israel (M.J.); Rabin Medical Center, Petach Tikva, Israel (R.K.); Centre Hospitalier Universitaire de Quebec, Canada (R.B.); Hospital Meixoeiro, Vigo, Spain (A.I.); Hadassah Hebrew University Medical Center, Jerusalem, Israel (H.D., G.Y.P.); MediQuest Research Group, Ocala, FL (R.F.); North Shore University Hospital, New York (R.J.); Victoria Heart and Vascular Center, TX (H.C.); Medinol Ltd, Tel Aviv, Israel (G.Y.P.); Massachusetts Institute of Technology, Cambridge (M.B., E.R.E.); and CBSET Inc, Lexington, MA (P.M.).
Elazer R EdelmanFrom Piedmont Heart Institute, Atlanta, GA (D.E.K.); Maasstad Hospital, Rotterdam, The Netherlands (P.C.S.); Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia (M.P.L.); Columbia University Medical Center and the Cardiovascular Research Foundation, New York (O.B.-Y., M.P., M.O.O., P.G., M.B.L., G.W.S.); Tel Aviv Medical Center, Israel (S.B.); Victoria Heart Institute Foundation, British Columbia, Canada (S.D.R.); Kaplan Medical Center, Rehovot, Israel (M.J.); Rabin Medical Center, Petach Tikva, Israel (R.K.); Centre Hospitalier Universitaire de Quebec, Canada (R.B.); Hospital Meixoeiro, Vigo, Spain (A.I.); Hadassah Hebrew University Medical Center, Jerusalem, Israel (H.D., G.Y.P.); MediQuest Research Group, Ocala, FL (R.F.); North Shore University Hospital, New York (R.J.); Victoria Heart and Vascular Center, TX (H.C.); Medinol Ltd, Tel Aviv, Israel (G.Y.P.); Massachusetts Institute of Technology, Cambridge (M.B., E.R.E.); and CBSET Inc, Lexington, MA (P.M.).
Martin B LeonFrom Piedmont Heart Institute, Atlanta, GA (D.E.K.); Maasstad Hospital, Rotterdam, The Netherlands (P.C.S.); Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia (M.P.L.); Columbia University Medical Center and the Cardiovascular Research Foundation, New York (O.B.-Y., M.P., M.O.O., P.G., M.B.L., G.W.S.); Tel Aviv Medical Center, Israel (S.B.); Victoria Heart Institute Foundation, British Columbia, Canada (S.D.R.); Kaplan Medical Center, Rehovot, Israel (M.J.); Rabin Medical Center, Petach Tikva, Israel (R.K.); Centre Hospitalier Universitaire de Quebec, Canada (R.B.); Hospital Meixoeiro, Vigo, Spain (A.I.); Hadassah Hebrew University Medical Center, Jerusalem, Israel (H.D., G.Y.P.); MediQuest Research Group, Ocala, FL (R.F.); North Shore University Hospital, New York (R.J.); Victoria Heart and Vascular Center, TX (H.C.); Medinol Ltd, Tel Aviv, Israel (G.Y.P.); Massachusetts Institute of Technology, Cambridge (M.B., E.R.E.); and CBSET Inc, Lexington, MA (P.M.).
Gregg W StoneFrom Piedmont Heart Institute, Atlanta, GA (D.E.K.); Maasstad Hospital, Rotterdam, The Netherlands (P.C.S.); Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia (M.P.L.); Columbia University Medical Center and the Cardiovascular Research Foundation, New York (O.B.-Y., M.P., M.O.O., P.G., M.B.L., G.W.S.); Tel Aviv Medical Center, Israel (S.B.); Victoria Heart Institute Foundation, British Columbia, Canada (S.D.R.); Kaplan Medical Center, Rehovot, Israel (M.J.); Rabin Medical Center, Petach Tikva, Israel (R.K.); Centre Hospitalier Universitaire de Quebec, Canada (R.B.); Hospital Meixoeiro, Vigo, Spain (A.I.); Hadassah Hebrew University Medical Center, Jerusalem, Israel (H.D., G.Y.P.); MediQuest Research Group, Ocala, FL (R.F.); North Shore University Hospital, New York (R.J.); Victoria Heart and Vascular Center, TX (H.C.); Medinol Ltd, Tel Aviv, Israel (G.Y.P.); Massachusetts Institute of Technology, Cambridge (M.B., E.R.E.); and CBSET Inc, Lexington, MA (P.M.).
Heart Foundation · US
Funding
Vascular Drug Delivery - Supplement for EquipmentR01GM049039 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI EDELMAN, ELAZER R · 1994 to 2019
$8.9MNIGMS NIH HHS R01 GM049039
Abstract
backgroundThe safety and efficacy of a novel cobalt alloy-based coronary stent with a durable elastomeric polymer eluting the antiproliferative agent ridaforolimus for treatment of patients with coronary artery disease is undetermined.
methodsA prospective, international 1:1 randomized trial was conducted to evaluate in a noninferiority design the relative safety and efficacy of ridaforolimus-eluting stents (RESs) and slow-release zotarolimus-eluting stents among 1919 patients undergoing percutaneous coronary intervention at 76 centers. Inclusion criteria allowed enrollment of patients with recent myocardial infarction, total occlusions, bifurcations lesions, and other complex conditions.
resultsBaseline clinical and angiographic characteristics were similar between the groups. Overall, mean age was 63.4 years, 32.5% had diabetes mellitus, and 39.7% presented with acute coronary syndromes. At 12 months, the primary end point of target lesion failure (composite of cardiac death, target vessel-related myocardial infarction, and target lesion revascularization) was 5.4% for both devices (upper bound of 1-sided 95% confidence interval 1.8%,
conclusionsIn the present trial, which allowed broad inclusion criteria, the novel RESs met the prespecified criteria for noninferiority compared with zotarolimus-eluting stents for the primary end point of target lesion failure at 12 months and had similar measures of late lumen loss. These findings support the safety and efficacy of RESs in patients who are representative of clinical practice. CLINICAL
trial registrationURL: http://www.clinicaltrials.gov. Unique identifier: NCT01995487.
Indexed as
Coronary Artery DiseaseDrug-Eluting StentsFemaleHumansMalePercutaneous Coronary InterventionProspective StudiesSirolimusridaforolimusSirolimuszotarolimuscoronary interventiondrug-eluting stentpercutaneousridaforolimusstent thrombosis
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT01995487ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.